Literature DB >> 3287837

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.

L A Carlson1, G Rosenhamer.   

Abstract

Consecutive survivors of a myocardial infarction from the Southern Hospital, below 70 years of age, were randomized into a Control group (n = 276) and a Treatment group (n = 279). The latter was openly prescribed the combination of clofibrate and nicotinic acid for serum lipid lowering. Each patient should remain in the study for 5 years and be seen regularly every 4 months at a special IHD outpatient clinic within the hospital. The concentration of serum cholesterol and triglyceride was lowered by 13% and 19%, respectively, in the Treatment group compared to the Control group. Total mortality was 82 cases in the Control group and 61 in the Treatment group, a 26% reduction (p less than 0.05). For patients above 60 years of age in the Treatment group the reduction in mortality was 28% (p less than 0.05). IHD mortality was reduced by 36% (p less than 0.01) in the Treatment group compared to the Control group. The beneficial effect of the serum lipid lowering treatment was related to the serum triglyceride concentration in two ways. First, it only occurred in patients with a triglyceride level greater than 1.5 mmol/l (n = 216). Secondly, it was most pronounced in the 44% of the treated patients who had a lowering of the serum triglyceride by 30% or more, and in this subgroup the reduction of IHD mortality was 60% (p less than 0.01). For serum cholesterol there were no such relations. The difference between serum triglycerides and cholesterol concerning these relations to the treatment outcome may be due to the fact that hypertriglyceridaemia was the most common hyperlipidaemia among our patients, occurring in 50%, while hypercholesterolaemia only occurred in 13%. Caution should be exercised in the interpretation of the results as the trial was not blind. However, the fact that the decrease in IHD deaths was directly related to the degree of serum triglyceride lowering indicates that it was the drug effect on serum lipids that was responsible for the beneficial effect of the treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3287837     DOI: 10.1111/j.0954-6820.1988.tb15891.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  92 in total

Review 1.  Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

2.  Should clofibrate still be prescribed?

Authors:  M G Dunnigan
Journal:  BMJ       Date:  1992-08-15

3.  Dietary and pharmacologic management of cholesterol.

Authors:  B M Rifkind
Journal:  Tex Heart Inst J       Date:  1990

4.  Asymptomatic hypertriglyceridaemia.

Authors:  S B Hulley; A L Avins
Journal:  BMJ       Date:  1992-02-15

Review 5.  Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story.

Authors:  Emma A Meagher
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 6.  Management strategies of dyslipidemia in the elderly: 2005.

Authors:  Tarek Helmy; Amar D Patel; Fadi Alameddine; Nanette K Wenger
Journal:  MedGenMed       Date:  2005-10-10

Review 7.  An overview of therapeutic interventions in myocardial infarction. Emphasis on secondary prevention.

Authors:  V Hinstridge; T M Speight
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 8.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

Review 9.  Cholesterol in patients with coronary heart disease: how low should we go?

Authors:  H B Rubins
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

Review 10.  Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.